Drug intelligence / Profile preview

Nanogam

Development stage
Phase 4
Lead developer
Prothya Biosolutions
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Nanogam is a human normal immunoglobulin (IVIg) solution containing 50 mg/ml (5%) of plasma proteins, of which at least 95% is immunoglobulin G (IgG). It is produced by Sanquin from large pools of human plasma, ensuring a broad spectrum of antibodies against various infectious agents. Nanogam is indicated for replacement therapy in patients with primary and secondary immunodeficiency syndromes and for immunomodulation in autoimmune conditions. Its therapeutic effects are mediated through the provision of passive immunity and complex interactions with the immune system, including the blockade of Fc receptors on phagocytic cells, neutralization of circulating autoantibodies and cytokines, and inhibition of complement-mediated damage. The product is stabilized with glucose and contains only trace amounts of IgA.

Brand names
Nanogam
Other names
human normal immunoglobulinintravenous immunoglobulinIVIg
02

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)Id (Tumor-specific idiotype immunoglobulin)

Beyond the preview

Go deeper on Nanogam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanogam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call